Plant stem cells could be fruitful source of low-cost cancer drug
A popular cancer drug could be produced cheaply and sustainably using stem cells derived from trees, a study suggests
2010-10-26
(Press-News.org) A popular cancer drug could be produced cheaply and sustainably using stem cells derived from trees, a study suggests.
Researchers have isolated and grown stem cells from a yew tree whose bark is a natural source of the anticancer compound paclitaxel. The development could enable the compound to be produced on a commercial scale at low cost, with no harmful by-products.
Scientists and engineers behind the development say the drug treatment – currently used on lung, ovarian, breast, head and neck cancer – could become cheaper and more widely available.
The study was carried out by the University of Edinburgh and the Unhwa Biotech company in Korea.
Currently, an extract from yew tree bark is used to industrially manufacture the compound paclitaxel. However, this process is expensive, requires supplies of mature trees, and creates environmentally damaging by-products.
Researchers claim that using stem cells – self-renewing tree cells which can be manipulated to produce large amounts of the active compound – would effectively create an abundant supply of the drug. The process would cost far less than conventional methods.
Scientists behind the project have also cultured stem cells from other plants with medical applications, indicating that the technique could be used to manufacture other important pharmaceuticals besides paclitaxel.
The study was published in Nature Biotechnology and supported by the Biotechnology and Biological Sciences Research Council and the Engineering and Physical Sciences Research Council.
Professor Gary Loake, of the University of Edinburgh's School of Biological Sciences, who led/took part in the study, said: "Plants are a rich source of medicine – around one in four drugs in use today is derived from plants. Our findings could deliver a low-cost, clean and safe way to harness the healing power of plants, potentially helping to treat cancer, and other conditions."
INFORMATION: END
ELSE PRESS RELEASES FROM THIS DATE:
2010-10-26
Patients with cancer found at the end of the large intestine called the rectum who receive one week of radiation therapy before surgery have a 50 percent reduction in chance that their cancer will return after 10 years, according to a large, randomized study presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
"We believe that this short course of radiation will open a new window of opportunities in the treatment of rectal cancer," Corrie Marijnen M.D., lead author of the study and a radiation ...
2010-10-26
Men with prostate cancer who take anticoagulants like aspirin in addition to radiation therapy or surgery may be able to cut their risk of dying of the disease by more than half, according to a large study presented on November 3, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego. The study involved more than 5,000 men with localized cancer whose disease had not spread beyond the prostate gland.
"Evidence has shown that anticoagulants may interfere with cancer growth and spread," Kevin Choe, M.D., Ph.D., lead author of ...
2010-10-26
Men treated for prostate cancer who were diagnosed after the start of routine screening had a significantly reduced risk of the disease spreading to other parts of the body (metastases) within 10 years of treatment, compared to men who were treated prior to the use of routine screening, according to the first study-of-its-kind presented November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
In 1993, routine prostate cancer screening became widely implemented through the use of a prostate specific antigen (PSA) test that was ...
2010-10-26
Prostate cancer patients who are treated with a combination of hormone therapy and radiation have a substantially improved chance of survival compared to patients who do not receive radiation, according to interim results of the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
From 1995 to 2005, 1,205 men with high-risk prostate cancer in the United States, the United Kingdom and Canada were randomly selected to receive hormone therapy alone or a ...
2010-10-26
WASHINGTON, Oct. 25, 2010 — Green gasoline is plants in your tank, motor vehicle fuel made from corn, cornstalks, sugarcane, and other crops. It also is gasoline made with recipes that reduce the need for harsh, potentially toxic ingredients like hydrofluoric acid or sulfuric acid that are used at about 210 oil refineries worldwide. Now scientists have found an answer to a half-century quest for a way to make gasoline in exactly that kind of greener, more environmentally-friendly way.
That advance highlights the second episode of a new video series, Prized Science: ...
2010-10-26
Men with prostate cancer treated with a specialized type of radiation called intensity modulated radiation therapy (IMRT) have fewer gastrointestinal complications compared to patients treated with conventional three-dimensional conformal radiotherapy (3D-CRT), according to a study presented November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
"With survivors living many years after treatment, it is very important to minimize gastrointestinal and urinary side effects to allow patients to live a full life after treatment," ...
2010-10-26
A lower dose of radiation used to reduce side effects is not as effective as the regular dose when given with the standard chemotherapy in the treatment of Hodgkin's lymphoma patients with early, intermediate-stage disease, according to a first-of-its-kind randomized study presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
In addition, the trial showed that a more intensive chemotherapy (BEACOPP) is not more effective than the standard chemotherapy treatment (ABVD) for these patients.
"This ...
2010-10-26
BOSTON (October 25, 2010) — Researchers from Tufts University pooled data from five previous epidemiological studies to investigate the prevalence of asthma in children in the Boston neighborhoods of Chinatown and Dorchester. Among children born in the United States, low socioeconomic status (SES) and exposure to pests (mice and cockroaches) were both associated with having asthma. Neither association was present in children born outside of the United States. The study was published online in advance of print in the Journal of Immigrant and Minority Health.
"In earlier ...
2010-10-26
Adding chemotherapy to radiation therapy for muscle invasive bladder cancer allows 67 percent of people to be free of disease in their bladders two years after treatment. This compares to 54 percent of people who receive radiation alone, according to the largest randomized study of its kind presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
"The trial shows that this treatment offers improved control of cancer within the bladder with acceptable long-term side effects and is therefore a ...
2010-10-26
Stereotactic radiation is an effective, long-term treatment for trigeminal neuralgia: a painful condition that occurs with increased frequency in patients with multiple sclerosis (MS). Radiation is noninvasive and has less negative side effects than other treatments, according to the longest follow-up in a study of its kind presented October 31, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Multiple sclerosis is a progressive neurological disease affecting about 300,000 Americans where the body's immune system attacks its own ...
LAST 30 PRESS RELEASES:
[Press-News.org] Plant stem cells could be fruitful source of low-cost cancer drug
A popular cancer drug could be produced cheaply and sustainably using stem cells derived from trees, a study suggests
